Cargando…
Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study
BACKGROUND: Rituximab (R) is a chimeric human-murine anti-CD20 monoclonal antibody used to treat B-cell lymphomas. Despite R remarkable activity against malignant cells, there are concerns that R may facilitate the occurrence of infections. This study is aimed to define risk factors for infections,...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716624/ https://www.ncbi.nlm.nih.gov/pubmed/23849292 http://dx.doi.org/10.1186/1471-2334-13-317 |